Stay updated on Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page
- Check7 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the full study content with a minimal page that includes a Home link and a revision note.SummaryDifference19%

- Check55 days agoChange DetectedAdded Melanoma and related topics (MedlinePlus Genetics) to the page’s related topics, and updated the revision indicator from v3.6.5 to v3.6.6. These changes serve metadata/navigation purposes rather than altering the study details.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now lacks the Melanoma label and related-topic links, indicating a pruning of topic signals and external resource references within the study details.SummaryDifference0.2%

- Check77 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5 on the page, signaling a small metadata/format update.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Plus Entinostat in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Entinostat in Melanoma Clinical Trial page.